TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02309879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine infusion
Description: Patients in Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine infusion
Description: Patients in Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
Study: NCT04376840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample and data record
Description: Blood sample and data record
Study: NCT03804021

Intervention type: GENETIC
Intervention: No Intervention
Description: Subjects who received ADVM-043 in a parent study (ADVANCE; NCT02168686)
Study: NCT06773429

Intervention type: DRUG
Intervention: E2 Valerate
Description: To experimentally elevate E2 levels females received 6mg of E2 valerate (Progynova21©) on two consecutive days (in total 12mg).

Intervention type: DRUG
Intervention: Placebo
Description: Placebo pills (blue-colored hard gelatine capsules filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) have been administered for the placebo-controlled condition.
Study: NCT01234740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bafetinib
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microdialysis
Description: Catheter placed intracerebrally during debulking craniotomy or stereotactic biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid chromatography
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: debulking craniotomy
Study: NCT03167112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Patients receive Oxaliplatin 85 mg/m2 over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Oxaliplatin is followed by Irinotecan (CPT-11) 180 mg/m2 over 90 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Oxaliplatin and Irinotecan is followed by Leucovorin (LV) 400 mg/m2 over 2 hours day1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Oxaliplatin and Irinotecan and Leucovorin is followed by Fluorouracil (5-FU) 400 mg/m2 bolus day1 and 2,400 mg/m2 46h continuous infusion.
Study: NCT03161912

Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: As per the treating physicians discretion.

Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: As per the treating physicians discretion.

Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: As per the treating physicians discretion.

Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: As per the treating physicians discretion.
Study: NCT02363361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Day 1. 800 mg, Day 2-14: 2 \* 400 mg per day
Study: NCT03509363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke physiotherapy home exercise video
Description: a set of exercise video with QR code provided in home exercise pamphlets
Study: NCT02997553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Each patient receive injection of indocyanine green just before surgery Specify total dose : 2.5 mg/ml (Intravenous use)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium99
Description: Each patient receives injection of Technetium 99 ( injected in subcutaneously) before surgery.~Lymphoscintigraphy is performed to identify the sentinel node

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optonuclear probe
Description: The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quest Camera
Description: The detection of sentinel lymph node will be conducted by a camera able to determine imagery of fluorescence during surgery.
Study: NCT03542903

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy
Description: Electroconvulsive therapy is administered through electrodes positioned bilaterally (for quicker efficacy) on the frontotemporal region.~The stimulation dose is determined by titration method, during the first ECT session.~The dose for therapeutic stimulation will be twice the seizure threshold. This dose may be increased as the crisis does not meet the effectiveness criteria, as is recommended.~For patients undergoing ECT, an intravenous injection of etomidate (between 0.1 and 0.7 mg/kg) and suxamethonium chloride (0.8 and 1.2 mg/kg) is performed. The required doses are adapted according to each patient by the anaesthetist and they are documented in the patients' files. A mixture of etomidate and propofol can be used in second-line or just propofol in third-line (no more than 2mg/kg).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy
Description: Electroconvulsive therapy is administered through electrodes positioned bilaterally (for quicker efficacy) on the frontotemporal region.~The stimulation dose is determined by titration method, during the first ECT session.~The dose for therapeutic stimulation will be twice the seizure threshold. This dose may be increased as the crisis does not meet the effectiveness criteria, as is recommended.~For patients undergoing ECT, an intravenous injection of etomidate (between 0.1 and 0.7 mg/kg) and suxamethonium chloride (0.8 and 1.2 mg/kg) is performed. The required doses are adapted according to each patient by the anaesthetist and they are documented in the patients' files. A mixture of etomidate and propofol can be used in second-line or just propofol in third-line (no more than 2mg/kg).
Study: NCT01983384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Processed EEG-guided anesthetic depth
Description: Investigators will undertake a randomized control trial in a cohort of older patients undergoing major non-cardiac surgery to receive either a control vs. an intervention of anesthesia as determined by a processed electroencephalogram

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Processed EEG-guided anesthetic depth
Description: Investigators will undertake a randomized control trial in a cohort of older patients undergoing major non-cardiac surgery to receive either a control vs. an intervention of anesthesia as determined by a processed electroencephalogram
Study: NCT02998203

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Organic diet
Description: Full organic diet from certified organic products as obtained from certified producers and cooked by a certified organic restaurant. five meals each day delivered to students.
Study: NCT01762735

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation
Description: Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water injection
Description: Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum.
Study: NCT04543266

Intervention type: PROCEDURE
Intervention: Surgery
Description: Resection of tumors

Intervention type: PROCEDURE
Intervention: Surgery
Description: Resection of tumors
Study: NCT02199314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Study: NCT04540666

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Targeted Controlled Propofol Infusion will be set at 1 micro gram/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Targeted Controlled Propofol Infusion will be set at 1 micro gram/ml.
Study: NCT01443364

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Prefilled syringes containing an injectable volume of 1ml of liquid Certolizumab Pegol (CZP) for single use at a dosage strength of 200 mg/ml. Injections will be given subcutaneously. CZP 400 mg at Week 0, 2 and 4, then continued as maintenance dose of 200 mg every 2 weeks until Week 50.
Study: NCT02251834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW)
Description: The primary mechanism used by the Community Health Worker (CHW) for delivering interventions will be a) home visits b) phone based contacts c) group level activities d) mobile technology. Ideally, each subject will have, at a minimum, 4 home visits and ten phone calls during months 3-12. Group visits will held twice a month. The Community Health Worker (CHW) intervention will be highly individualized and tailored to unique circumstances of each patient and we expect home visits, calls, ProMobile usage and group visits to vary by patient.

Intervention type: OTHER
Group type: OTHER
Intervention: usual care and health education brochures every 4 months.
Description: Patients randomized to the control group will receive usual care.
Study: NCT03905239

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: algorithm
Description: clinical examination and procalcitonin assessment
Study: NCT01044745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Stem cell transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: graft versus host disease prophylaxis/therapy
Description: Undergo graft versus host disease prophylaxis/therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: graft-versus-tumor induction therapy
Description: Undergo graft-versus-tumor induction therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immunosuppressive therapy
Description: Undergo immunosuppressive therapy
Study: NCT03036683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation will be administered for 20 minutes using a CE approved stimulator (NeuroConn, Ilmenau, Germany).
Study: NCT02434328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab ophthalmic solution
Description: Ophthalmic solution for IVT injection administered as a 6 mg/50 µL dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept ophthalmic solution
Description: Ophthalmic solution for IVT injection administered as a 2 mg/50 µL dose
Study: NCT00358410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW679769 oral tablets
Description: 2x GW679769 60mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablets to match experimental intervention
Study: NCT01291771

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Invasive FFR + CFR measurements are performed during coronary angiography using a pressure guide wire
Description: The guide is placed in the distal segment of the coronary artery to measure instantaneously distal pressure and temperature with a tip sensor. Proximal pressure and temperature are being measured from the probe used to catheterize the coronary vessel and from the shaft of the guide. After basal measurement, intracoronary injection of 150µg of adenosine is performed to induce peripheral vasodilatation leading to hyperaemia in the vessel. Additional injection of 3mL 0.9% saline bolus at room temperature at the time of hyperaemia is performed to calculate CFR from transit mean time. FFR and CFR are being recorded at the time of hyperaemia. Subsequently IMR is being calculated from distal pressure and transit mean time. The measurements will be performed in the LAD, circumflex and right coronary arteries.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Invasive FFR + CFR measurements are performed during coronary angiography using a pressure guide wire
Description: The guide is placed in the distal segment of the coronary artery to measure instantaneously distal pressure and temperature with a tip sensor. Proximal pressure and temperature are being measured from the probe used to catheterize the coronary vessel and from the shaft of the guide. After basal measurement, intracoronary injection of 150µg of adenosine is performed to induce peripheral vasodilatation leading to hyperaemia in the vessel. Additional injection of 3mL 0.9% saline bolus at room temperature at the time of hyperaemia is performed to calculate CFR from transit mean time. FFR and CFR are being recorded at the time of hyperaemia. Subsequently IMR is being calculated from distal pressure and transit mean time. The measurements will be performed in the LAD, circumflex and right coronary arteries.
Study: NCT04595422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Undergo training consisting of a 60-minute educational session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive lung cancer screening educational materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT01755767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Tivantinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Tivantinib tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study: NCT01023048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preimplantation diagnosis
Description: genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)
Study: NCT00186940

Intervention type: DRUG
Intervention: Rasburicase
Description: Rasburicase 0.2 mg/kg/dose by the intravenous route for up to 7 days.
Study: NCT02590094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab or intravitreal ziv-aflibercept
Description: Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab or intravitreal ziv-aflibercept
Description: Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab or intravitreal ziv-aflibercept
Description: Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab or intravitreal ziv-aflibercept
Description: Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.
Study: NCT03036683

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
Study: NCT02961933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apneic oxygenation
Description: Nasal cannula apneic oxygenation
Study: NCT02421224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
Study: NCT02961933

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-oxgenation with NRB, NIPPV, BVM
Description: Pre-oxygenation with non-rebreather mask, non-invasive positive pressure ventilation, or bag-valve mask
Study: NCT04388319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Zonisamide (100 mg/daily) for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Halo G6 e-cigarette
Description: G6 e-cigarette for ad libitum use for two weeks prior to complete switch day.
Study: NCT00326183

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VAQTA®
Description: 0.5 ml injection VAQTA®; 2nd 0.5 ml injection VAQTA® 24 week period of treatment.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VAQTA®
Description: 0.5 ml injection VAQTA®; 2nd 0.5 ml injection VAQTA® 24 week period of treatment.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ProQuad
Description: 0.5 ml injection ProQuad; 2nd 0.5 ml injection ProQuad®. 24 week period of treatment.
Study: NCT02095366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Intravenous administration Patient receives simultaneously IV morphine administration and IN placebo spray.~Pain is controlled by:~* at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg~* at 10 minutes and if NPRS\>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg~* at 20 minutes and if NPRS\>3: Pacebo (1 spray) + morphine IV 0,05mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV placebo administration and IN sufentanil spray.~Pain is controlled by:~* at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV~* at 10 minutes and if NPRS\>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV~* at 20 minutes and if NPRS\>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous administration Patient receives simultaneously IV placebo administration and IN sufentanil spray.~Pain is controlled by:~* at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV~* at 10 minutes and if NPRS\>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV~* at 20 minutes and if NPRS\>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV morphine administration and IN placebo spray.~Pain is controlled by:~* at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg~* at 10 minutes and if NPRS\>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg~* at 20 minutes and if NPRS\>3: Pacebo (1 spray) + morphine IV 0,05mg/kg
Study: NCT03803475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 labeled PSMA-11
Description: Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if there is presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography-computed tomography (PET/CT)
Description: Positron emission tomography-computed tomography (PET/CT) is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography (PET) scanner and an x-ray computed tomography (CT) scanner, to acquire sequential images from both devices in the same session

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography-magnetic resonance imaging (PET/MRI)
Description: A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan in a single session
Study: NCT04348565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Care Programme
Description: 20-week Diabetes Care Programme consists of three Diabetes Conversation Map sessions in 8 weeks with 3-4 weeks intervals, then two teleconsultations at week 12th and week 16th
Study: NCT03379857

Intervention type: OTHER
Group type: OTHER
Intervention: Drug urinal test
Description: Non Applicable
Study: NCT00559845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 600 milligrams per meter squared (mg/m\^2) as an intravenous (i.v.) bolus over ≤15 minutes every 3 weeks for 4 cycles.
Study: NCT04140643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozonated water delivering device effects on the oral health of pregnant women
Description: Oral Hygiene instructions and use of an ozonated water delivering device in pregnant women for a period of 75 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene instructions
Description: Oral Hygiene instructions